Proton MR spectroscopy of the brain. Neuroimaging Clin N Am 1999 May;9(2):379-95
Date
05/11/1999Pubmed ID
10318721Scopus ID
2-s2.0-0033049850 (requires institutional sign-in at Scopus site) 30 CitationsAbstract
Over the past five decades, MR spectroscopy has evolved from an analytical chemistry tool to a noninvasive clinical examination on FDA approved equipment with an AMA billing code. While proton MR spectroscopy has dominated current clinical studies, interest in other nucleii has arisen, particularly P-31 for the evaluation of membrane lipids, and C-13 for the evaluation of glutamate neurotransmission and excitotoxicity. Currently, the most common neuroradiological diagnostic indication is the differentation of suspected cerebral neoplasms for post-treatment effects, abcesses, subacute infarcts, demyelinating disease, and other non-neoplastic processes. Recent recommendations for monitoring multiple sclerosis treatment suggest an increasing role for MR spectroscopy in the future.
Author List
Rand SD, Prost R, Li SJAuthors
Shi-Jiang Li PhD, MS Emeritus Professor in the Biophysics department at Medical College of WisconsinScott Rand PhD, MS, MD Emeritus Professor in the Radiology department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
BrainBrain Abscess
Brain Diseases
Brain Neoplasms
Carbon Isotopes
Cerebral Infarction
Demyelinating Diseases
Diagnosis, Differential
Glutamic Acid
Humans
Magnetic Resonance Spectroscopy
Membrane Lipids
Multiple Sclerosis
Neurotransmitter Agents
Phosphorus Isotopes
Protons
United States
United States Food and Drug Administration
